Side-by-side · Research reference

OvagenvsSS-31

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

ATheoreticalHUMAN-REVIEWED2/42 cited

BPhase 3HUMAN-REVIEWED9/43 cited

Ovagen

Khavinson Bioregulator · Ovarian

OvarianTarget tissue

Di/Tri-peptidePeptide length

AnimalEvidence tier

Oral / SQ · Protocol varies

SS-31

Cardiolipin-binding · Mitochondrial protective

40 mgDaily doseSzeto 2014

Phase 3Evidence levelSzilagyi 2009 Szeto 2014

~3 hrHalf-life

SQ · Abdomen · Once daily

01Mechanism of Action

Parameter

Ovagen

SS-31

Primary target

Ovarian tissue chromatin complexes

Cardiolipin in inner mitochondrial membraneSzeto 2014

Pathway

Tissue-specific peptide → Nuclear chromatin binding → Gene expression modulation → Cellular differentiation

Cardiolipin binding → cristae stabilisation → ETC integrity → reduced ROS + preserved ATP synthesisSzeto 2014 Szilagyi 2009

Downstream effect

Proposed ovarian functional support, fertility regulation, hormonal homeostasis restoration

Mitochondrial bioenergetic preservation; cardio-, neuro-, and reno-protective effects in animal + clinical studiesSzeto 2014

Feedback intact?

Presumed physiological — Khavinson peptides described as regulatory, not replacement

—

Origin

Extracted from bovine/porcine ovarian tissue; short synthetic peptides (2–4 amino acids)

Synthetic tetrapeptide D-Arg-Dmt-Lys-Phe-NH₂; cell-permeable, mitochondrial-selectiveSzeto 2014

Antibody development

—

02Dosage Protocols

Parameter

Ovagen

SS-31

Standard dose

10–20 mg / day (oral) or 1–2 mg SQ

Extrapolated from Khavinson-school protocols; no ovagen-specific PubMed dose studies.

40 mg / day SQ (clinical trials)Szeto 2014

Anecdotal community range 5-10 mg/day. Phase 3 trials use 40 mg.

Frequency

Once daily or cyclical (10–20 days per month)

Cyclical protocols common in Khavinson bioregulator tradition.

Once daily

Evidence basis

Theoretical / Russian-tradition

Multiple Phase 3 trials (Barth, AMD, ischemia-reperfusion)Szeto 2014 Szilagyi 2009

Duration

4–12 weeks per cycle

Khavinson protocols typically 1–3 months; repeat cycles as needed.

Indefinite for mitochondrial disease; cycled for healthspan use

Route

Oral (capsule) or subcutaneous

Oral absorption assumed for short peptides; SQ route mirrors other Khavinson bioregulators.

—

Lower / starter dose

—

5 mg / day (anecdotal)

Reconstitution

—

Bacteriostatic water

Timing

—

Morning fasted preferred; pre-workout for exercise-induced mitochondrial stress

Half-life

—

~3 h plasma; tissue uptake longer

04Side Effects & Safety

Parameter

Ovagen

SS-31

Reported adverse events

None documented in indexed literature

—

Theoretical hormonal effects

Ovarian stimulation — monitor for estrogen-sensitive conditions

—

Injection site reaction

Possible mild erythema (SQ route)

Erythema, mild pruritus

Long-term safety

Unknown — no PubMed-indexed RCTs

Phase 3 data over 24+ months; no major safety signalsSzeto 2014

GI symptoms

—

Nausea (uncommon)

Headache

—

Reported in some Phase 3 trials

Cardiovascular

—

Cardio-protective in studies; no signal of harm

Pregnancy / OB

—

Avoid — insufficient data

Absolute Contraindications

Ovagen

·Active hormone-sensitive malignancy (breast, ovarian, endometrial)
·Pregnancy

SS-31

·Pregnancy / breastfeeding
·Hypersensitivity to peptide

Relative Contraindications

Ovagen

·History of estrogen-sensitive tumors (monitor)
·Polycystic ovary syndrome (PCOS) — theoretical ovarian hyperstimulation risk
·Endometriosis or fibroids (estrogen-responsive conditions)

SS-31

·None established

05Administration Protocol

Parameter

Ovagen

SS-31

1. Oral route

Typical dose: 10–20 mg once daily. Capsule form — taken on empty stomach, 20–30 min before meals. Khavinson tradition suggests morning administration.

Add bacteriostatic water per label. Light-protected handling.

2. Subcutaneous route

1–2 mg per injection. Reconstitute lyophilised powder with sterile water if required. Inject into abdomen or thigh; rotate sites.

SQ — abdomen or thigh. Rotate sites.

3. Cyclical protocol

Common pattern: 10–20 days on, 10 days off. Aligns with menstrual cycle phases in some protocols. Repeat cycles for 2–3 months, then assess.

Morning fasted; pre-workout for exercise-augmented mitochondrial stress.

4. Storage

Lyophilised: room temperature, light-protected. Reconstituted: refrigerate 2–8 °C, use within 7–14 days.

Lyophilised: refrigerate, light-protected. Reconstituted: refrigerate ≤30 days.

5. Needle

—

29–31G, 4–8 mm insulin syringe.

06Stack Synergy

Ovagen

— no documented stacks

SS-31

+ MOTS-c

Moderate

View MOTS-c →

SS-31 and MOTS-c address mitochondrial decline through complementary axes. SS-31 protects existing mitochondrial structure (cardiolipin binding, cristae stabilisation). MOTS-c upregulates AMPK/PGC-1α, triggering biogenesis of new mitochondria. Together they pair preservation with renewal — anecdotally favoured in healthspan and post-cardio-event recovery protocols.

SS-31: 5–10 mg SQ · daily morning
MOTS-c: 5 mg SQ · 2× per week pre-workout
Primary benefit: Mitochondrial preservation + biogenesis